| Linkage to Care for Persons With Hep C Infection (NCT05397067) | Carilion Clinic | 2022-07-12 |
| Possible Differences in HCC Course Depending on DAA Treatment (NCT05376943) | Medical University of Warsaw | 2022-05-10 |
| Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (NCT05140941) | Catherine Anne Chappell | 2022-04-04 |
| Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs (NCT04943588) | Queen Mary University of London | 2021-11-01 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects (NCT04309734) | Atea Pharmaceuticals, Inc. | 2021-10-01 |
| The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection (NCT04774107) | PharmaEssentia | 2020-11-26 |
| HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in Brussels (NCT04610762) | Centre Hospitalier Universitaire Saint Pierre | 2020-11-17 |
| Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir (NCT04382404) | Catherine Anne Chappell | 2020-10-22 |
| The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study (NCT03987503) | University of California, San Francisco | 2020-07-01 |
| Rapid HCV RNA Testing and LInkage to Care (NCT04302948) | University of New Mexico | 2020-03-02 |
| Evaluating the Chain of Addiction Care (CAC) (NCT05401136) | Radboud University Medical Center | 2020-03-01 |
| Re-engaging Patients With Hepatitis C Into Care (NCT04029246) | Glasgow Royal Infirmary | 2019-11-01 |
| Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) (NCT03888729) | Partners in Health | 2019-08-26 |
| Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA). (NCT05542615) | University of Guadalajara | 2019-08-01 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection (NCT04019717) | Atea Pharmaceuticals, Inc. | 2019-06-20 |
| Evaluation of Dried Blood Spot for HCV RNA Testing (NCT03896087) | Foundation for Innovative New Diagnostics, Switzerland | 2019-04-01 |
| SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C (NCT04070235) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2019-03-29 |
| ATTIC - Access To Treat in the Community (NCT03797066) | King's College Hospital NHS Trust | 2019-03-23 |
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C (NCT04952207) | Qing XIe | 2019-03-06 |
| Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy (NCT03903185) | Ain Shams University | 2019-03-01 |
| Eliminating HCV Infection Among PWUD (NCT05474781) | Vancouver Infectious Diseases Centre | 2019-02-22 |
| Voices From the Black Community: Hepatitis C Research Participation (NCT04202081) | University of North Carolina, Chapel Hill | 2019-02-21 |
| Hepatitis C Surveillance With Linkage to Care of Patients From Non-ID Departments in Jiangsu (NCT03772002) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2019-01-01 |
| Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years (NCT03764345) | National Liver Institute, Egypt | 2018-12-06 |
| Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients (NCT03880682) | Istanbul University | 2018-11-01 |
| People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (NCT03520660) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2018-10-19 |
| Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings (NCT03343925) | Kirby Institute | 2018-08-17 |
| Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4 (NCT03578640) | King Fahad Medical City | 2018-07-01 |
| Evaluation of Multiple HCV Diagnosis Pathways for Efficacy, Cost Effectiveness and Cure in NHS Tayside (NCT03513796) | NHS Tayside | 2018-06-20 |
| Evaluation of HCV Viremia Testing Approaches Among PWID in Georgia (NCT03594838) | Foundation for Innovative New Diagnostics, Switzerland | 2018-05-21 |
| Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children (NCT05091008) | Mansoura University Children Hospital | 2018-03-01 |
| Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] (NCT03480932) | Johns Hopkins Bloomberg School of Public Health | 2018-02-02 |
| Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy (NCT03549312) | Saskatchewan Health Authority - Regina Area | 2018-02-01 |
| Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection (NCT03057847) | Elizabeth Krans, MD | 2018-01-30 |
| Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego (NCT03551002) | University of California, San Diego | 2018-01-01 |
| MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (NCT03003338) | Hannover Medical School | 2017-10-24 |
| A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic (NCT03235154) | Community Research Initiative of New England | 2017-10-11 |
| Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial (NCT03551444) | Ain Shams University | 2017-10-01 |
| Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment (NCT03207399) | Duke University | 2017-09-15 |
| Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients (NCT03413696) | University of California, San Diego | 2017-09-08 |
| Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients (NCT03117569) | Kirby Institute | 2017-08-21 |
| Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence (NCT03164902) | Proteus Digital Health, Inc. | 2017-07-21 |
| Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs (NCT03170076) | Assiut University | 2017-07-01 |
| Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan (NCT03200379) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2017-06-15 |
| 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis (NCT03186365) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2017-06-12 |
| KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C (NCT03995485) | Kawin Technology Share-holding Co., Ltd. | 2017-06-07 |
| Integrated Treatment of Hepatitis C Virus Infection (NCT03155906) | Haukeland University Hospital | 2017-05-18 |
| Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers (NCT03038763) | University of Pennsylvania | 2017-05-11 |
| Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir (NCT03063879) | Tehran University of Medical Sciences | 2017-04-01 |
| Curing HCV in Incarcerated Patients (NCT03018353) | San Francisco Department of Public Health | 2017-03-05 |
| Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia (NCT03342261) | Hospices Civils de Lyon | 2017-03-01 |
| Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C (NCT03416491) | Kawin Technology Share-holding Co., Ltd. | 2017-02-15 |
| Hepatitis C Virus(HCV) Heart and Lung Study (NCT02858180) | Duke University | 2016-12-01 |
| Eliminate Hepatitis C/EC Partnership Evaluation Protocol (NCT04061551) | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 2016-12-01 |
| Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection (NCT02765490) | Janssen Research & Development, LLC | 2016-11-09 |
| Anticipated and Perceived Benefits Following Hepatitis C Treatment (NCT03000023) | University of North Carolina, Chapel Hill | 2016-10-01 |
| Transforming the Cascade Of Hepatitis C Care (NCT03226509) | University of Pittsburgh | 2016-09-01 |
| Cohort Study on People Who Inject Drugs in Senegal (NCT03459768) | French National Agency for Research on AIDS and Viral Hepatitis | 2016-08-24 |
| Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C (NCT03453346) | Kawin Technology Share-holding Co., Ltd. | 2016-08-05 |
| A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection (NCT02498015) | Kirby Institute | 2016-08-01 |
| Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection (NCT02707991) | Johns Hopkins University | 2016-07-01 |
| Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon (NCT02804386) | PharmEvo Pvt Ltd | 2016-06-01 |
| Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035) (NCT02759315) | Merck Sharp & Dohme LLC | 2016-05-03 |
| HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (NCT02660905) | Ottawa Hospital Research Institute | 2016-04-01 |
| Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients (NCT02969668) | Universitätsklinikum Hamburg-Eppendorf | 2016-03-01 |
| Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC (NCT02771405) | National Hepatology & Tropical Medicine Research Institute | 2016-03-01 |
| A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029) (NCT02666352) | Merck Sharp & Dohme LLC | 2016-01-22 |
| Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection (NCT02597166) | University Health Network, Toronto | 2016-01-01 |
| Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) (NCT02624063) | Federal University of São Paulo | 2015-12-01 |
| The Patient-Reported Outcomes Project of HCV-TARGET (NCT02601820) | University of North Carolina, Chapel Hill | 2015-11-01 |
| Directly Observed Therapy for HCV in Chennai, India (NCT02541409) | Johns Hopkins Bloomberg School of Public Health | 2015-09-01 |
| Primary Prevention Hepatocellular Carcinoma by Metformin (NCT02319200) | Assistance Publique - Hôpitaux de Paris | 2015-06-01 |
| Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages (NCT04177043) | Egyptian Liver Hospital | 2015-06-01 |
| Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO (NCT02461745) | Kaiser Permanente | 2015-06-01 |
| A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (NCT02421211) | Janssen Sciences Ireland UC | 2015-05-19 |
| Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection (NCT02340962) | TaiGen Biotechnology Co., Ltd. | 2015-05-01 |
| Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection (NCT03119025) | Russian Academy of Medical Sciences | 2015-05-01 |
| Hepatitis C Virus Infection in Patients With Hemoglobinopathies (NCT03149289) | Società Italiana Talassemie ed Emoglobinopatie | 2015-03-01 |
| A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (NCT02268864) | Janssen-Cilag International NV | 2015-01-01 |
| An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C (NCT01679834) | Hoffmann-La Roche | 2014-11-24 |
| Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy (NCT02469012) | University of Wuerzburg | 2014-10-01 |
| An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease (NCT02262728) | Janssen Research & Development, LLC | 2014-09-30 |
| A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C (NCT02206932) | University of California, San Francisco | 2014-08-01 |
| An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients (NCT02118597) | Hoffmann-La Roche | 2014-05-01 |
| Observational Study in HCV Chronic Infection (NCT01945008) | Istituto Superiore di Sanità | 2014-04-01 |
| Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Patients (NCT03057236) | University of North Carolina, Chapel Hill | 2014-03-01 |
| Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C (NCT02120274) | Federal University of São Paulo | 2014-03-01 |
| Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection (NCT01147107) | University of Hawaii | 2014-02-01 |
| Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (NCT02027116) | GeneOne Life Science, Inc. | 2014-01-01 |
| A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (NCT01938625) | Janssen R&D Ireland | 2013-12-12 |
| Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 (NCT01994486) | University of Florida | 2013-12-01 |
| Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy (NCT02060058) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2013-11-01 |
| Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107) (NCT01945294) | Merck Sharp & Dohme LLC | 2013-10-10 |
| A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection (NCT01846832) | Janssen-Cilag International NV | 2013-09-01 |
| Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C (NCT01925183) | Markus Peck-Radosavljevic | 2013-08-01 |
| A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients (NCT01928147) | Presidio Pharmaceuticals, Inc. | 2013-08-01 |
| Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) (NCT01919125) | Merck Sharp & Dohme LLC | 2013-08-01 |
| Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C (NCT01871662) | Rottapharm | 2013-08-01 |
| A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects (NCT01879462) | GlaxoSmithKline | 2013-06-14 |
| Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection (NCT01872936) | Santaris Pharma A/S | 2013-06-01 |